Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive agree...
2024-04-29 08:17:37 ET More on pre-market losers & stocks. Deutsche Bank AG (DB) Q1 2024 Earnings Call Transcript Deutsche Bank May Knock Q1 Estimates Out Of The Park Buy Altimmune's Potential Market Disruption With Pemvidutide Deutsche Bank reports 10%Y/...
2024-04-26 08:26:58 ET Losers: reAlpha Tech Corp. ( AIRE ) -15% . Processa Pharmaceuticals ( PCSA ) -14% . Saia SAIA -13% after Q1 earnings release . Boyd Gaming Corp. BYD -12% after Q1 earnings release . Barfresh Food Group ( BRFH )...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 1.6% to $12 on volume of 162,538,711 shares Safe & Green Holdings Corp. (SGBX) rose 52.0% to $0.219 on volume of 135,670,644 shares Tesla Inc. (TSLA) rose 5.0% to $170.18 on volume of 124,333,134 shares...
2024-04-25 13:06:40 ET Gainers: Loar Holdings ( LOAR ) +63% . Safe & Green Holdings Corp ( SGBX ) +61% . YY Group Holding Limited Class A Ordinary Shares ( YYGH ) +50% . Barfresh Food Group ( BRFH ) +40% . Processa Pharmaceuticals ( ...
A look at the top 10 most actives in the United States Safe & Green Holdings Corp. (SGBX) rose 52.1% to $0.2192 on volume of 34,842,044 shares Processa Pharmaceuticals Inc. (PCSA) rose 46.9% to $2.38 on volume of 31,858,013 shares PROSHARES TRUST (SQQQ) rose 5.0% to $12.4002 on volume...
2024-04-24 10:00:42 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance BofA watched clients retract $2B last week as the S&P dropped ...
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...
2024-03-19 18:09:10 ET Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript March 19, 2024, 04:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO ...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...